Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat - The effect of AT1-R blocker on the hepatic fibrosis

Tuncer, I; Ozbek, H; Ugras, S; Bayram, I

doi:10.1078/0940-2993-00309

Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat - The effect of AT1-R blocker on the hepatic fibrosis

Copy For Citation

Tuncer I., Ozbek H., Ugras S., Bayram I.

EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, vol.55, pp.159-166, 2003 (SCI-Expanded)

Publication Type: Article / Article
Volume: 55
Publication Date: 2003
Doi Number: 10.1078/0940-2993-00309
Journal Name: EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.159-166
Van Yüzüncü Yıl University Affiliated: No

Abstract

Background/Aim: Angiotensin converting enzyme (ACE) and angiotensin II (AT-II) have been suggested to play an important role in liver fibrogenesis. There is a significant relationship between inheritance of hightened expression of transforming growth factor beta1 (TGF-beta1) and AT-II and the development of progressive hepatic fibrosis. The purpose of this study was to investigate the effects of captopril. an ACE inhibitor and candesartan cilexetil, an AT-II type I receptor (AT1-R) blocker, on liver fibrosis induced in rats by carbon tetrachloride (CCl4) administration.